Pulmonary aspergillosis

Seminars in Respiratory and Critical Care Medicine

Volumn 29, Issue 2, 2008, Pages 103-110

  Thompson III, George R ^a   Patterson, Thomas F ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Aspergillus fumigatus; Pulmonary aspergillosis; Voriconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; CORTICOSTEROID; ECHINOCANDIN; INFLIXIMAB; ITRACONAZOLE; POSACONAZOLE; TRIAZOLE; VORICONAZOLE;

ASPERGILLUS; BRONCHOPULMONARY ASPERGILLOMA; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; HUMAN; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; MORTALITY; MYCOLOGY; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; TRACHEOBRONCHITIS; TREATMENT DURATION;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; HUMANS; IMMUNOCOMPROMISED HOST; LUNG DISEASES, FUNGAL;

EID: 41149137805     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1063849     Document Type: Review

References (41)

1. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America (IDSA). Clin Infect Dis 2008;46(3):327-360
2. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. 13 Aspergillus Study Group. Medicine 2000;79:250-260
3. Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin Infect Dis 2002;34:780-789
4. Warris A, Voss A, Abrahamsen TG, Verweij PE. Contamination of hospital water with Aspergillus fumigatus and other molds. Clin Infect Dis 2002;34:1159-1160
5. Torres HA, Rivero GA, Lewis RE, et al. Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus. Diagn Microbiol Infect Dis 2003;46:25-28
6. Patterson JE, Peters J, Calhoon JH, et al. Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients. Transpl Infect Dis 2000;2:22-28
7. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine 1999;78:123-138
8. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001;344:1099-1100
9. Cohen MS, Isturiz RE, Malech HL, et al. Fungal infection in chronic granulomatous disease: the importance of the phagocyte in defense against fungi. Am J Med 1981;71:59-66
10. Denning DW. Aspergillosis in "nonimmunocompromised" critically ill patients. Am J Respir Crit Care Med 2004;170:580-581
11. Gerson SL, Talbot GH, Hurwitz S, et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984;100:345-351
12. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997;175:1459-1466
13. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998;26:781-803
14. Greene R. The radiological spectrum of pulmonary aspergillosis. Med Mycol 2005;43(Suppl 1):S147-S154
15. Denning DW, Follansbee SE, Scolaro M, et al. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 1991;324:654-662
16. Kramer MR, Denning DW, Marshall SE, et al. Ulcerative tracheobronchitis after lung transplantation: a new form of invasive aspergillosis. Am Rev Respir Dis 1991;144(3 Pt 1):552-556
17. Binder RE, Faling LJ, Pugatch RD, Mahasaen C, Snider GL. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine 1982;61:109-124
18. Gefter WB, Weingrad TR, Epstein DM, Ochs RH, Miller WT. "Semi-invasive" pulmonary aspergillosis: a new look at the spectrum of aspergillus infections of the lung. Radiology 1981;140:313-321
19. Hope WW, Walsh TJ, Denning DW. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005;43(Suppl 1):S207-S238
20. Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003;37(Suppl 3):S265-S280
21. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32:358-366
22. Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002;110:685-692
23. Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000;342:756-762
24. Munoz P, Alcala L, Sanchez Conde M, et al. The isolation of Aspergillus fumigatus from respiratory tract specimens in heart transplant recipients is highly predictive of invasive aspergillosis. Transplantation 2003;75:326-329
25. Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996;100:171-178
26. Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002;20:1898-1906
27. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001;97:1604-1610
28. Verweij PE, Mennink-Kersten MA. Issues with galactomannan testing. Med Mycol 2006;44(Suppl):179-183
29. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004;39:199-205
30. Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go. Clin Infect Dis 2006;42:487-489
31. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32:686-693
32. Comely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007;44:1289-1297
33. Eiden C, Peyriere H, Cociglio M, et al. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database. Ann Pharmacother 2007;41:755-763
34. Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003;37(Suppl 3):S157-S187
35. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415
36. De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs 2001;61(Suppl 1):27-37
37. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004;57:218-222
38. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-347
39. Comely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-359
40. Bennett JE. Echinocandins for candidemia in adults without neutropenia. N Engl J Med 2006;355:1154-1159
41. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004;39:797-802